Home > Insider Trading > Filing (0001209191-21-029115)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1445499	Impel Neuropharma Inc	IMPL	()	CA

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1089744	Promod Haque	525 University Avenue Suite 800 Palo Alto CA 94301	No	No	Yes	No
1535261	Jeffrey Crowe	525 University Avenue Suite 800 Palo Alto CA 94301	No	No	Yes	No
1726084	Erik Jon Kossow	525 University Avenue Suite 800 Palo Alto CA 94301	No	No	Yes	No
1842721	Norwest Venture Partners Xiv, Lp	525 University Avenue Suite 800 Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-04-27	98,927	$13.50	98,927	No	4	C	Direct
Common Stock	Acquisiton	2021-04-27	2,153,271	$0.00	2,252,198	No	4	C	Direct
Common Stock	Acquisiton	2021-04-27	825,000	$15.00	3,077,198	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	5% Convertible Note due 2021	Disposition	2021-04-27	0	$0.00	98,927	$13.50
Common Stock	Series D Preferred Stock	Disposition	2021-04-27	35,256,206	$0.00	2,153,271	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2021-12-31	No	4	C	Direct
0			No	4	C	Direct

Footnotes

The securities shown represent securities held of record by Norwest Venture Partners XIV, LP ("NVP XIV"). Genesis VC Partners XIV, LLC ("Genesis XIV") is the general partner of NVP XIV and may be deemed to have sole voting and dispositive power over the shares held by NVP XIV. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XIV, and Jeffrey Crowe, Promod Haque and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities and Messrs. Crowe, Haque and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
The shares of the Issuer's Series D Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock on a 16.37332-for-one basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering of Common Stock (the "IPO") and had no expiration date.
The convertible promissory note was issued by the Issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the Issuer's Common Stock set forth above upon the closing of the IPO at $13.50 per share (90% of the IPO price).